The DOI matches its Crossref record; 94 of the 94 references it cites were found in a registry or an index.
Liver microphysiological systems development guidelines for safety risk assessment in the pharmaceutical industry
Abstract
The liver is critical to consider during drug development because of its central role in the handling of xenobiotics, a process which often leads to localized and/or downstream tissue injury. Our ability to predict human clinical safety outcomes with animal testing is limited due to species differences in drug metabolism and disposition, while traditional human in vitro liver models often lack the necessary in vivo physiological fidelity. To address this, increasing numbers of liver microphysiological systems (MPS) are being developed, however the inconsistency in their optimization and characterization often leads to models that do not possess critical levels of baseline performance that is required for many pharmaceutical industry applications. Herein we provide a guidance on best approaches to benchmark liver MPS based on 3 stages of characterization that includes key performance metrics and a 20 compound safety test set. Additionally, we give an overview of frequently used liver injury safety assays, describe the ideal MPS model, and provide a perspective on currently best suited MPS contexts of use. This pharmaceutical industry guidance has been written to help MPS developers and end users identify what could be the most valuable models for safety risk assessment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These consortia not only promote MPS and OoC adoption but also generate lists of reference compounds relevant to various organ systems (Ainslie et al., 2019; Baudy et al., 2020; Hardwick et al., 2020; Peters et al., 2020; Phillips et al., 2020; Pointon et al., 2021).”
From Considering future qualification for regulatory science in the early development of microphysiological systems: a case study of microthrombosis in a Vessel-on-Chip (2024) · cites this paper as Baudy et al., 2020
In the citing paper
“Guided by the IQ MPS affiliate’s roadmap on liver MPS19, which states that in vitro models for predicting drug-induced liver injury (DILI) that meet its guidelines are more likely to exhibit higher predictive validity than those that do not”
From Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology (2022) · cites this paper as [19]
In the citing paper
“Albumin and urea production are widely accepted as functional markers for cultured hepatocytes with the goal of reaching computed production levels observed in human liver in vivo (~20–105 µg and 56–159 µg per 106 hepatocytes per day, respectively)19,26.”
From Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology (2022) · cites this paper as [19]
Citations
Cites
Ostapowicz, G., Fontana, R. J., Schiødt, F. V., Larson, A., Davern, T. J., Han, S. H. B., McCashland, T. M., Shakil, A. O., Hay, J. E., Hynan, L., et al. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-12-200212170-00007 · Cited by 2,227
Heroux, J., & Gharib, A. M. (2008) · Molecular Imaging in Oncology · doi:10.3109/9781420019957-3 · Cited by 2,187
Concordance of the toxicity of pharmaceuticals in humans and in animals
Olson, H., Betton, G., Robinson, D., Thomas, K., Monro, A., Kolaja, G., Lilly, P., Sanders, J., Sipes, G., Bracken, W., et al. (2000) · Regulatory Toxicology and Pharmacology · doi:10.1006/rtph.2000.1399 · Cited by 2,050
Microscale culture of human liver cells for drug development
Khetani, S. R., & Bhatia, S. N. (2008) · Nature Biotechnology · doi:10.1038/nbt1361 · Cited by 1,219
Maschmeyer, I., Lorenz, A. K., Schimek, K., Hasenberg, T., Ramme, A. P., Hübner, J., Lindner, M., Drewell, C., Bauer, S., Thomas, A., et al. (2015) · Lab on a Chip · doi:10.1039/c5lc00392j · Cited by 861
Chalasani, N., Fontana, R. J., Bonkovsky, H. L., Watkins, P. B., Davern, T., Serrano, J., Yang, H., & Rochon, J. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.09.011 · Cited by 755
Bell, C. C., Hendriks, D. F. G., Moro, S. M. L., Ellis, E., Walsh, J., Renblom, A., Fredriksson Puigvert, L., Dankers, A. C. A., Jacobs, F., Snoeys, J., et al. (2016) · Scientific Reports · doi:10.1038/srep25187 · Cited by 739
R EGULATION OF E NZYMES OF THE U REA C YCLE AND A RGININE M ETABOLISM
Morris, S. M. (2002) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.22.110801.140547 · Cited by 725
Sitaxsentan Therapy for Pulmonary Arterial Hypertension
Barst, R. J., Langleben, D., Frost, A., Horn, E. M., Oudiz, R., Shapiro, S., McLaughlin, V., Hill, N., Tapson, V. F., Robbins, I. M., et al. (2004) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200307-957oc · Cited by 706
McKenzie, R., Fried, M. W., Sallie, R., Conjeevaram, H., Di Bisceglie, A. M., Park, Y., Savarese, B., Kleiner, D., Tsokos, M., Luciano, C., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199510263331702 · Cited by 616
Interconnected Microphysiological Systems for Quantitative Biology and Pharmacology Studies
Edington, C. D., Chen, W. L. K., Geishecker, E., Kassis, T., Soenksen, L. R., Bhushan, B. M., Freake, D., Kirschner, J., Maass, C., Tsamandouras, N., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-22749-0 · Cited by 487
Drug-Induced Liver Injury Network (DILIN) Prospective Study: Rationale, Design and Conduct
Fontana, R. J., Watkins, P. B., Bonkovsky, H. L., Chalasani, N., Davern, T., Serrano, J., & Rochon, J. (2009) · Drug Safety · doi:10.2165/00002018-200932010-00005 · Cited by 486
Multi-Organ toxicity demonstration in a functional human in vitro system composed of four organs
Oleaga, C., Bernabini, C., Smith, A. S. T., Srinivasan, B., Jackson, M., McLamb, W., Platt, V., Bridges, R., Cai, Y., Santhanam, N., et al. (2016) · Scientific Reports · doi:10.1038/srep20030 · Cited by 442
McGill, M. R., Williams, C. D., Xie, Y., Ramachandran, A., & Jaeschke, H. (2012) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2012.08.015 · Cited by 421
Rodríguez-Antona, C., Donato, M. T., Boobis, A., Edwards, R. J., Watts, P. S., Castell, J. V., & Gómez-Lechón, M.-J. (2002) · Xenobiotica · doi:10.1080/00498250210128675 · Cited by 420
Nguyen, D. G., Funk, J., Robbins, J. B., Crogan-Grundy, C., Presnell, S. C., Singer, T., & Roth, A. B. (2016) · PLOS ONE · doi:10.1371/journal.pone.0158674 · Cited by 379
Self-citationChen, M., Borlak, J., & Tong, W. (2013) · Hepatology · doi:10.1002/hep.26208 · Cited by 348
Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury
Proctor, W. R., Foster, A. J., Vogt, J., Summers, C., Middleton, B., Pilling, M. A., Shienson, D., Kijanska, M., Ströbel, S., Kelm, J. M., et al. (2017) · Archives of Toxicology · doi:10.1007/s00204-017-2002-1 · Cited by 328
Self-citationMorgan, R. E., Trauner, M., van Staden, C. J., Lee, P. H., Ramachandran, B., Eschenberg, M., Afshari, C. A., Qualls, C. W., Lightfoot-Dunn, R., & Hamadeh, H. K. (2010) · Toxicological Sciences · doi:10.1093/toxsci/kfq269 · Cited by 325
Multi-cell type human liver microtissues for hepatotoxicity testing
Messner, S., Agarkova, I., Moritz, W., & Kelm, J. M. (2013) · Archives of Toxicology · doi:10.1007/s00204-012-0968-2 · Cited by 319
Banks, A. T., Zimmerman, H. J., Ishak, K. G., & Harter, J. G. (1995) · Hepatology · doi:10.1002/hep.1840220320 · Cited by 301
Hepatotoxicity by drugs: The most common implicated agents
Björnsson, E. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17020224 · Cited by 254
The Metabolism of Diclofenac - Enzymology and Toxicology Perspectives
Tang, W. (2003) · Current Drug Metabolism · doi:10.2174/1389200033489398 · Cited by 238
Novel human hepatic organoid model enables testing of drug-induced liver fibrosis in vitro
Leite, S. B., Roosens, T., El Taghdouini, A., Mannaerts, I., Smout, A. J., Najimi, M., Sokal, E., Noor, F., Chesne, C., & van Grunsven, L. A. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2015.11.026 · Cited by 234
A human liver microphysiology platform for investigating physiology, drug safety, and disease models
Vernetti, L. A., Senutovitch, N., Boltz, R., DeBiasio, R., Ying Shun, T., Gough, A., & Taylor, D. L. (2016) · Experimental Biology and Medicine · doi:10.1177/1535370215592121 · Cited by 226
Mitigating the toxic effects of anticancer immunotherapy
Gangadhar, T. C., & Vonderheide, R. H. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.245 · Cited by 222
Tsamandouras, N., Chen, W. L. K., Edington, C. D., Stokes, C. L., Griffith, L. G., & Cirit, M. (2017) · The AAPS Journal · doi:10.1208/s12248-017-0122-4 · Cited by 222
Aleo, M. D., Luo, Y., Swiss, R., Bonin, P. D., Potter, D. M., & Will, Y. (2014) · Hepatology · doi:10.1002/hep.27206 · Cited by 215
A microfluidic hepatic coculture platform for cell-based drug metabolism studies
Novik, E., Maguire, T. J., Chao, P., Cheng, K. C., & Yarmush, M. L. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.11.010 · Cited by 212
Maximal Rates of Excretion and Synthesis of Urea in Normal and Cirrhotic Subjects
Rudman, D., DiFulco, T. J., Galambos, J. T., Smith, R. B., Salam, A. A., & Warren, W. D. (1973) · Journal of Clinical Investigation · doi:10.1172/jci107410 · Cited by 207
Ware, B. R., Berger, D. R., & Khetani, S. R. (2015) · Toxicological Sciences · doi:10.1093/toxsci/kfv048 · Cited by 195
Takayama, K., Morisaki, Y., Kuno, S., Nagamoto, Y., Harada, K., Furukawa, N., Ohtaka, M., Nishimura, K., Imagawa, K., Sakurai, F., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1413481111 · Cited by 193
Fey, S. J., & Wrzesinski, K. (2012) · Toxicological Sciences · doi:10.1093/toxsci/kfs122 · Cited by 188
Interactions between the cytochrome P450 system and the second-generation antipsychotics
Prior, T. I., & Baker, G. B. (2003) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0312 · Cited by 188
McGoon, M. D., Frost, A. E., Oudiz, R. J., Badesch, D. B., Galie, N., Olschewski, H., McLaughlin, V. V., Gerber, M. J., Dufton, C., Despain, D. J., et al. (2009) · Chest · doi:10.1378/chest.08-1028 · Cited by 187
Monticello, T. M., Jones, T. W., Dambach, D. M., Potter, D. M., Bolt, M. W., Liu, M., Keller, D. A., Hart, T. K., & Kadambi, V. J. (2017) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2017.09.006 · Cited by 186
Self-citationRole of mitochondrial permeability transition in diclofenac-induced hepatocyte injury in rats
Masubuchi, Y., Nakayama, S., & Horie, T. (2002) · Hepatology · doi:10.1053/jhep.2002.31871 · Cited by 184
Porceddu, M., Buron, N., Roussel, C., Labbe, G., Fromenty, B., & Borgne-Sanchez, A. (2012) · Toxicological Sciences · doi:10.1093/toxsci/kfs197 · Cited by 181
Funk, C. (2001) · Toxicology · doi:10.1016/s0300-483x(01)00460-7 · Cited by 177
Wilson, Z. E., Rostami‐Hodjegan, A., Burn, J. L., Tooley, A., Boyle, J., Ellis, S. W., & Tucker, G. T. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01881.x · Cited by 174
Ju, C., & Uetrecht, J. (2002) · Current Drug Metabolism · doi:10.2174/1389200023337333 · Cited by 166
Clay, K. D., Hanson, J. S., Pope, S. D., Rissmiller, R. W., Purdum, P. P., & Banks, P. M. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-6-200503210-00121 · Cited by 160
Three-dimensional perfused human in vitro model of non-alcoholic fatty liver disease
Kostrzewski, T. M., Cornforth, T. V., Snow, S., Ouro-Gnao, L., Rowe, C., Large, E. M., & Hughes, D. J. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i2.204 · Cited by 160
Köck, K., Ferslew, B. C., Netterberg, I., Yang, K., Urban, T. J., Swaan, P. W., Stewart, P. W., & Brouwer, K. L. R. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.113.054304 · Cited by 159
Lee-Montiel, F. T., George, S. M., Gough, A., Sharma, A. D., Wu, J., DeBiasio, R., Vernetti, L. A., & Taylor, D. L. (2017) · Experimental Biology and Medicine · doi:10.1177/1535370217703978 · Cited by 158
Kizawa, H., Nagao, E., Shimamura, M., Zhang, G., & Torii, H. (2017) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2017.04.004 · Cited by 156
Kalgutkar, A. S. S., Vaz, A. D. N., Lame, M. E., Henne, K. R., Soglia, J. R., Zhao, S. X., Abramov, Y. A., Lombardo, F., Collin, C., Hendsch, Z. S., et al. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.001735 · Cited by 155
Usui, T., Mise, M., Hashizume, T., Yabuki, M., & Komuro, S. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.028860 · Cited by 153
Shah, F., Leung, L., Barton, H. A., Will, Y., Rodrigues, A. D., Greene, N., & Aleo, M. D. (2015) · Toxicological Sciences · doi:10.1093/toxsci/kfv152 · Cited by 148
In Vitro Metabolism of Tolcapone to Reactive Intermediates: Relevance to Tolcapone Liver Toxicity
Smith, K. S., Smith, P. L., Heady, T. N., Trugman, J. M., Harman, W. D., & Macdonald, T. L. (2003) · Chemical Research in Toxicology · doi:10.1021/tx025569n · Cited by 147
Rashidi, H., Luu, N. T., Alwahsh, S. M., Ginai, M., Alhaque, S., Dong, H., Tomaz, R. A., Vernay, B., Vigneswara, V., Hallett, J. M., et al. (2018) · Archives of Toxicology · doi:10.1007/s00204-018-2280-2 · Cited by 145
Bauman, J. N., Kelly, J. M., Tripathy, S., Zhao, S. X., Lam, W. W., Kalgutkar, A. S. S., & Obach, R. S. (2009) · Chemical Research in Toxicology · doi:10.1021/tx800407w · Cited by 140
Strauss, A. W., Bennett, C. D., Donohue, A. M., Rodkey, J. A., & Alberts, A. W. (1977) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)39927-1 · Cited by 137
Kenna, J. G., Taskar, K. S., Battista, C., Bourdet, D. L., Brouwer, K. L. R., Brouwer, K. R., Dai, D., Funk, C., Hafey, M. J., Lai, Y., et al. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1222 · Cited by 130
Hummer, M., Kurz, M., Kurzthaler, I., OBERBAUER, H., Miller, C., & Fleischhacker, W. W. (1997) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199708000-00012 · Cited by 126
Shaw, P. J., Ganey, P. E., & Roth, R. A. (2010) · Toxicological Sciences · doi:10.1093/toxsci/kfq168 · Cited by 123
Exploratory toxicology as an integrated part of drug discovery. Part I: Why and how
Hornberg, J. J., Laursen, M., Brenden, N., Persson, M., Thougaard, A., Toft, D. B., & Mow, T. J. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.12.008 · Cited by 118
Hemodynamic flow improves rat hepatocyte morphology, function, and metabolic activity in vitro
Dash, A., Simmers, M. B., Deering, T. G., Berry, D. J., Feaver, R. E., Hastings, N. E., Pruett, T. L., LeCluyse, E. L., Blackman, B. R., & Wamhoff, B. R. (2013) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00331.2012 · Cited by 108
Long, T. J., Cosgrove, P. A., Dunn, R. T., Stolz, D. B., Hamadeh, H. K., Afshari, C. A., McBride, H. J., & Griffith, L. G. (2016) · Drug Metabolism and Disposition · doi:10.1124/dmd.116.071456 · Cited by 96
Bioactivation of Diclofenacin Vitroandin Vivo: Correlation to Electrochemical Studies
Madsen, K., Skonberg, C., Jurva, U., Cornett, C., Hansen, S. H., Johansen, T. N., & Olsen, J. (2008) · Chemical Research in Toxicology · doi:10.1021/tx700419d · Cited by 92
A Predictive 3D Multi-Scale Model of Biliary Fluid Dynamics in the Liver Lobule
Meyer, K., Ostrenko, O., Bourantas, G., Morales-Navarrete, H., Porat-Shliom, N., Segovia-Miranda, F., Nonaka, H., Ghaemi, A., Verbavatz, J.-M., Brusch, L., et al. (2017) · Cell Systems · doi:10.1016/j.cels.2017.02.008 · Cited by 91
Minimizing DILI risk in drug discovery — A screening tool for drug candidates
Schadt, S., Simon, S., Kustermann, S., Boess, F., McGinnis, C., Brink, A., Lieven, R., Fowler, S., Youdim, K., Ullah, M., et al. (2015) · Toxicology in Vitro · doi:10.1016/j.tiv.2015.09.019 · Cited by 89
Self-citationGao, X., & Liu, Y. (2017) · Cell Biology and Toxicology · doi:10.1007/s10565-017-9383-z · Cited by 87
Hosey, C. M., Chan, R., & Benet, L. Z. (2015) · The AAPS Journal · doi:10.1208/s12248-015-9845-2 · Cited by 86
In Vitro Metabolism of 2-Acetylbenzothiophene: Relevance to Zileuton Hepatotoxicity
Joshi, E. M., Heasley, B. H., Chordia, M. D., & Macdonald, T. L. (2004) · Chemical Research in Toxicology · doi:10.1021/tx0341409 · Cited by 85
Effects of entacapone and tolcapone on mitochondrial membrane potential
Haasio, K., Koponen, A., Penttilä, K. E., & Nissinen, E. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)02383-x · Cited by 78
Sarkar, U., Ravindra, K. C., Large, E. M., Young, C. L., Rivera‐Burgos, D., Yu, J., Cirit, M., Hughes, D. J., Wishnok, J. S., Lauffenburger, D. A., et al. (2017) · Drug Metabolism and Disposition · doi:10.1124/dmd.116.074005 · Cited by 75
The Role of Conjugation in Hepatotoxicity of Troglitazone in Human and Porcine Hepatocyte Cultures
Kostrubsky, V. E., Sinclair, J. F., Ramachandran, V., Venkataramanan, R., Wen, Y. H., Kindt, K., Galchev, G., Rose, R., Sinz, S., & Strom, S. C. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)13660-4 · Cited by 72
Maximizing the impact of microphysiological systems with in vitro – in vivo translation
Cirit, M., & Stokes, C. L. (2018) · Lab on a Chip · doi:10.1039/c8lc00039e · Cited by 72
Hartman, J. C., Brouwer, K. R., Mandagere, A., Melvin, L., & Gorczynski, R. J. (2010) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y10-060 · Cited by 71
Calcium ion-dependent vesicle fusion in the conversion of proalbumin to albumin
Judah, J. D., & Quinn, P. S. (1978) · Nature · doi:10.1038/271384a0 · Cited by 70
Burbank, M., Burban, A., Sharanek, A., Weaver, R. J., Guguen‐Guillouzo, C., & Guillouzo, A. (2016) · Drug Metabolism and Disposition · doi:10.1124/dmd.116.071373 · Cited by 69
A Microfabricated Platform for Generating Physiologically-Relevant Hepatocyte Zonation
McCarty, W. J., Usta, O. B., & Yarmush, M. L. (2016) · Scientific Reports · doi:10.1038/srep26868 · Cited by 67
Watkins, P. B., Dubé, L. M., Walton-Bowen, K. L., CAMERON, C. M., & Kasten, L. E. (2007) · Drug Safety · doi:10.2165/00002018-200730090-00006 · Cited by 62
Hu, D. M., Wu, C., Li, Z., Liu, Y., Fan, X., Wang, Q., & Ding, R.-G. (2015) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2015.02.018 · Cited by 59
Dragović, S., Vermeulen, N. P. E., Gerets, H. H. J., Hewitt, P. G., Ingelman‐Sundberg, M., Park, B. K., Juhila, S., Snoeys, J., & Weaver, R. J. (2016) · Archives of Toxicology · doi:10.1007/s00204-016-1845-1 · Cited by 59
Self-citationLiver histology during Mipomersen therapy for severe hypercholesterolemia
Hashemi, N., Odze, R. D., McGowan, M. P., Santos, R. D., Stroes, E. S. G., & Cohen, D. E. (2014) · Journal of clinical lipidology · doi:10.1016/j.jacl.2014.08.002 · Cited by 58
Latest Industry Information on the Safety Profile of Levofloxacin in the US
Kahn, J. B. (2001) · Chemotherapy · doi:10.1159/000057842 · Cited by 58
Microphysiological Systems (“Organs‐on‐Chips”) for Drug Efficacy and Toxicity Testing
Low, L. A., & Tagle, D. A. (2017) · Clinical and Translational Science · doi:10.1111/cts.12444 · Cited by 58
Yan, Z., Maher, N., Torres, R., & Huebert, N. D. (2007) · Analytical Chemistry · doi:10.1021/ac0701029 · Cited by 54
Kelly, D. L., Conley, R. R., Richardson, C. M., Tamminga, C. A., & Carpenter, W. T. (2003) · Annals of Clinical Psychiatry · doi:10.1023/b:acli.0000008171.90644.f8 · Cited by 53
Kenna, J. G., Stahl, S. H., Eakins, J. A., Foster, A. J., Andersson, L. C., Bergare, J., Billger, M., Elebring, M., Elmore, C. S., & Thompson, R. A. (2015) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.220491 · Cited by 48
Erve, J. C. L., Gauby, S., Maynard, J. W., Svensson, M. A., Tonn, G., & Quinn, K. P. (2013) · Chemical Research in Toxicology · doi:10.1021/tx4001144 · Cited by 48
Kamalian, L., Douglas, O., Jolly, C., Snoeys, J., Simic, D., Monshouwer, M., Williams, D. P., Park, B. K., & Chadwick, A. E. (2018) · Toxicology in Vitro · doi:10.1016/j.tiv.2018.08.001 · Cited by 46
Insight into hepatotoxicity: The troglitazone experience†
Watkins, P. B. (2005) · Hepatology · doi:10.1002/hep.20598 · Cited by 45
Tetsuka, K., Ohbuchi, M., & Tabata, K. (2017) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2017.05.010 · Cited by 44
Weaver, R. J., Betts, C. J., Blomme, E. A. G., Gerets, H. H. J., Jensen, K. G., Hewitt, P. G., Juhila, S., Labbe, G., Liguori, M. J., Mesens, N., et al. (2017) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2017.1341489 · Cited by 41
Self-citationMicrofluidic Cell Culture Platforms to Capture Hepatic Physiology and Complex Cellular Interactions
Bale, S. S., & Borenstein, J. T. (2018) · Drug Metabolism and Disposition · doi:10.1124/dmd.118.083055 · Cited by 37
Telithromycin and Acute Liver Failure
Graham, D. J. (2006) · New England Journal of Medicine · doi:10.1056/nejmc066372 · Cited by 30
Akuta, N., Sezaki, H., Suzuki, F., Kawamura, Y., Hosaka, T., Kobayashi, M., Kobayashi, M., Saitoh, S., Suzuki, Y., Arase, Y., et al. (2015) · Journal of Medical Virology · doi:10.1002/jmv.24360 · Cited by 20
O'Brien, T. M., Carlson, R. M., Oliveira, P. J., & Wallace, K. B. (2006) · Chemical Research in Toxicology · doi:10.1021/tx060132r · Cited by 12
High-Throughput Analysis of Mitochondrial Oxygen Consumption
Hynes, J., Swiss, R. L., & Will, Y. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7831-1_4 · Cited by 12
Tikunov, A. P., Shim, Y.-S., Bhattarai, N., Siler, S. Q., Soldatow, V. Y., LeCluyse, E. L., McDunn, J. E., Watkins, P. B., & Macdonald, J. M. (2017) · Toxicology in Vitro · doi:10.1016/j.tiv.2017.08.021 · Cited by 6
[Liver cell necrosis during administration of clozapine].
Je, H., Vogtländer, L., Ha, V., & Thunnissen, P. L. M. (1994) · PubMed · Cited by 4
Research works printed but not linked: 15
- R. Becker , A.Chakravarty , D.Cho , O.Faris , S.Fitzpatrick , N.Hunter , I.Irony , S.Lababidi , C.Leptak , W.Mattes , E.Mishina , K.O'Callaghan , M.Pacanowski , E.Papadopoulos , V.Peiris , R.Puri , M.Robb , H.Rogers , R.Sherman , R.Sridhara , R.Temple , A.Trentacosti , P.Turfle , S.Wang , H.Hamilton , P.McInnes , L.McShane and M.Shah , BEST (Biomarkers, EndpointS, and other Tools) Resource , Silver Spring (MD) , 2018
- Kizawa, 2017, Biochem. Biophys. Rep., 10, 186
- Chen, 2013, Hepatology, 58, 388, 10.1002/hep.26208 · DOI · Paper page
- Hosey, 2016, AAPS J., 18, 251, 10.1208/s12248-015-9845-2 · DOI
- Shah, 2015, Toxicol. Sci., 147, 500, 10.1093/toxsci/kfv152 · DOI · Paper page
- Kock, 2014, Drug Metab. Dispos., 42, 665, 10.1124/dmd.113.054304 · DOI · Paper page
- Morgan, 2010, Toxicol. Sci., 118, 485, 10.1093/toxsci/kfq269 · DOI · Paper page
- Aleo, 2014, Hepatology, 60, 1015, 10.1002/hep.27206 · DOI · Paper page
- Proctor, 2017, Arch. Toxicol., 91, 2849, 10.1007/s00204-017-2002-1 · DOI · Paper page
- Bell, 2016, Sci. Rep., 6, 25187, 10.1038/srep25187 · DOI · Paper page
- Ballmer, 1990, Am. J. Physiol., 259, E797
- Hovens, 1994, Ned. Tijdschr. Geneeskd., 138, 363
- Prior, 2003, J. Psychiatry Neurosci., 28, 99
- Kostrubsky, 2000, Drug Metab. Dispos., 28, 1192
- Stork, 1997, J. Toxicol., 35, 105
Cited by
Human organs-on-chips for disease modelling, drug development and personalized medicine
Ingber, D. E. (2022) · Nature Reviews Genetics · doi:10.1038/s41576-022-00466-9 · Cited by 1,589
Organs-on-chips: into the next decade
Low, L. A., Mummery, C., Berridge, B. R., Austin, C. P., & Tagle, D. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0079-3 · Cited by 1,029
Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology
Ewart, L., Apostolou, A., Briggs, S. A., Carman, C. V., Chaff, J. T., Heng, A. R., Jadalannagari, S., Janardhanan, J., Jang, K.-J., Joshipura, S. R., et al. (2022) · Communications Medicine · doi:10.1038/s43856-022-00209-1 · Cited by 337
The evolving role of investigative toxicology in the pharmaceutical industry
Pognan, F., Beilmann, M., Boonen, H. C. M., Czich, A., Dear, G., Hewitt, P., Mow, T., Oinonen, T., Roth, A., Steger-Hartmann, T., et al. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00633-x · Cited by 255
Self-citation3D cell culture models: Drug pharmacokinetics, safety assessment, and regulatory consideration
Wang, H., Brown, P. C., Chow, E. C. Y., Ewart, L., Ferguson, S. S., Fitzpatrick, S., Freedman, B. S., Guo, G. L., Hedrich, W., Heyward, S., et al. (2021) · Clinical and Translational Science · doi:10.1111/cts.13066 · Cited by 212
“, metabolic clearance, RNA isolations, and lower sensitivity protein secretion assays), and (3) the ability to clearly image cell morphology using conventional laboratory systems.”
BackgroundSelf-citation
Metadata
- Authors
- Baudy, A. R., Otieno, M. A., Hewitt, P., Gan, J., Roth, A., Keller, D., Sura, R., Van Vleet, T. R., & Proctor, W. R.
- Affiliations
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Springhouse (US)
- Merck KGaA, Darmstadt (Germany) (DE)
- Bristol-Myers Squibb (United States) (US)
- F. Hoffmann-La Roche AG (CH)
- Sanofi (United States) (US)
- AbbVie (United States) (US)
- AbbVie, Inc.
- Genentech (US)
- Corresponding author
- Baudy, Andreas R.
- ORCID
- Venue
- Lab on a Chip
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2020
- Volume
- 20
- Issue
- 2
- Pages
- 215-225
- ISSN
- 1473-0189 (ISSN-L)
- 1473-0197
- OpenAlex
- W2990102938
- Cited by
- 150
- References
- 94
- Citations by year
- 2026: 22 · 2025: 27 · 2024: 22 · 2023: 20 · 2022: 23 · 2021: 27 · 2020: 9
- FWCI
- 1.19
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Lab on a Chip (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
- Keywords
- liver-on-a-chip, liver injury, hepatotoxicity, model characterization, model benchmarking, key performance indicators, in vitro liver models, drug metabolism, species differences in drug metabolism, drug development
- MeSH terms
- Animals, Drug Industry, Drug Evaluation, Preclinical, Pharmaceutical Preparations, Humans, Liver, Risk Assessment, Lab-On-A-Chip Devices
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.